MarketPulse

chronic rhinosinusitis with nasal polyps

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi

Sanofi's Lunsekimig Clears Key Phase 2 Hurdles in Asthma and Sinus Disease

Sanofi's bispecific antibody lunsekimig met primary endpoints in phase 2 asthma and chronic rhinosinusitis studies, though atopic dermatitis trial missed targets.
SNYchronic rhinosinusitis with nasal polypsatopic dermatitis
GlobeNewswire Inc.GlobeNewswire Inc.··Upstream Bio, Inc.

Upstream Bio's Verekitug Shows Strong Phase 2 Results in Nasal Polyp Treatment

Upstream Bio presented additional Phase 2 data for verekitug in chronic rhinosinusitis with nasal polyps, meeting primary endpoints with significant surgical intervention reduction.
UPBPhase 2 clinical trialmonoclonal antibody
GlobeNewswire Inc.GlobeNewswire Inc.··Upstream Bio, Inc.

Upstream Bio to Unveil Extended VIBRANT Trial Data on Verekitug at AAAAI 2026

Upstream Bio will present expanded VIBRANT trial data on verekitug for chronic rhinosinusitis with nasal polyps at AAAAI 2026, including new efficacy analyses accounting for rescue therapy use.
UPBPhase 2 clinical trialmonoclonal antibody